Skip to main content
. 2019 Sep 4;14(9):e0221941. doi: 10.1371/journal.pone.0221941

Table 4. Treatment regimens and response assessment at the point of PB sampling.

Treated WM (N = 33)
N (%)
Treatment regimen Rituximab containing 28 (84.8)
Total number of previous treatment regimens 1 15 (45.4)
2 11 (33.3)
> = 3 5 (15.2)
Response assessment at PB sampling CR 4 (12.1)
PR 21 (63.6)
MR 3 (9.1)
SD+PD 3 (9.1)
Not evaluated 2 (6.1)